Polyethylene Glycol 3500
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
- Polyethylene Glycol 3500
- Polyethylene Glycol 3500: From Constipation to Congenital Ichthyosiform Erythroderma
Polyethylene Glycol 3500: From Constipation to Congenital Ichthyosiform Erythroderma
One-Sentence Summary
Polyethylene glycol 3500 (PEG 3500) is an osmotic laxative, originally used to treat constipation and also listed for dry eye conditions. The TxGNN model predicts it may be effective for congenital ichthyosiform erythroderma, but no clinical trials and no publications currently support this prediction, so it is a computational signal only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Constipation disorder (also dry eye syndrome and xerophthalmia in the knowledge graph); no approved indication text is available in the US license record |
| Predicted New Indication | Congenital ichthyosiform erythroderma |
| TxGNN Prediction Score | 99.73% |
| Evidence Level | L5 |
| US Market Status | Cancelled only (no currently valid license) |
| Number of NDAs | 1 (one cancelled ANDA, not an NDA) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, PEG 3500 is a hydrophilic polymer used as an osmotic laxative. Its efficacy in constipation is established, but there is no data connecting it to inherited skin-scaling disorders.
A speculative link is that a hydrophilic polymer could act as a humectant or emollient-like agent, helping hydrate the stratum corneum in ichthyosis. This idea is untested and unsupported by any evidence. Oral PEG 3500 is minimally absorbed, so it would be unlikely to reach the skin systemically.
The very high TxGNN score (0.997) reflects a computational prediction only. Two other related skin conditions were also predicted: self-healing collodion baby (99.60%) and lamellar ichthyosis (99.38%). All three have the same lack of supporting evidence. Established treatments for ichthyosis (emollients, keratolytics, retinoids) already exist, and PEG 3500 has no demonstrated advantage.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ANDA078915 (cancelled) | Polyethylene Glycol (3350), Mylan Institutional Inc. | Powder, for solution | Not specified |
Safety Considerations
The knowledge graph links PEG 3500 to contraindication relationships with the following conditions. These come from graph data, not from package insert text, and should be confirmed against the label:
- Gastrointestinal: ileus, paralytic ileus, intestinal obstruction, toxic megacolon, pyloric stenosis, appendicitis, familial visceral myopathy
- Cardiovascular and renal: hypertension, congestive heart failure, cardiovascular and heart disease, kidney disease, anuria, pyoureter
- Metabolic and endocrine: diabetes mellitus, hyperglycemia, diabetic ketoacidosis, hypercalcemia, nephrocalcinosis, potassium deficiency, phosphorus metabolism disease, hyperthyroidism, Graves disease, thyrotoxicosis
- Neurological: epilepsy
- Eye: angle-closure glaucoma, closed-angle glaucoma, conjunctivitis, eye infectious disease
No drug interaction records were found. Please refer to the package insert for official warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score. There are no clinical trials or publications, the mechanism is unknown, oral PEG 3500 is minimally absorbed, and the only US license is cancelled. Effective ichthyosis treatments already exist.
To proceed, the following is needed:
- Mechanism of action data for PEG 3500 and a plausible biological link to ichthyosis
- Route and formulation assessment, since a topical product would be needed and none is currently identified
- Package insert warnings and contraindications to complete safety screening
- Preclinical or early exploratory evidence (for example, skin hydration or barrier studies) showing benefit over existing emollients
- A literature and trial search to confirm that no relevant studies exist
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.